The diabetes care landscape is set for significant changes with the anticipated launch of the Dexcom G7 continuous glucose monitor (CGM) and substantial price reductions for semaglutide products, including Ozempic and Wegovy. This was discussed in a recent episode of the Diabetes Dialogue podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP. The hosts provided insights into these developments that promise to enhance diabetes management for patients and healthcare providers alike.
On December 1, 2023, the Dexcom G7 will be available through durable medical equipment channels, with pharmacy access following shortly after. The new sensor boasts a 15-day wear period, extending its functionality with a built-in 12-hour grace period. It retains the familiar form factor and accuracy that users expect. With initial integration for devices such as the Omnipod 5 and iLet, and plans for Control-IQ+ compatibility later, the G7 aims to streamline diabetes management significantly.
During the discussion, Isaacs and Bellini highlighted how the extended sensor life can reduce the burden of frequent sensor changes. This is particularly beneficial as the adoption of CGMs increases in primary care settings and among individuals with type 2 diabetes. Notably, the initial FDA approval is for adults aged 18 and older, with pediatric usage expected as additional data becomes available.
The conversation then transitioned to the newly cleared Smart Basal feature within the G7 app. This tool utilizes CGM data to assist healthcare providers and patients in adjusting basal insulin doses, specifically for glargine. By analyzing comprehensive glycemic patterns rather than relying on isolated fasting values, the system aims to enhance titration processes. It includes customizable safeguards against hypoglycemia and identifies an optimal dose once glucose levels stabilize. This is particularly crucial in primary care settings, where under-titration of basal insulin is a common issue.
In addition to advancements in technology, significant pricing changes for semaglutide were also addressed. The new self-pay pricing structure allows patients to access Ozempic for $199 for the first two months, followed by $349 thereafter. This marks a notable decrease from previous cash prices and aligns Wegovy pricing across all doses. While affordability continues to be a critical concern, these adjustments are viewed as a positive step towards aligning U.S. prices with international standards, potentially expanding access for those who do not qualify for traditional insurance coverage or patient assistance programs.
The hosts also discussed updated criteria for assistance programs, the ongoing availability of copay cards, and similar price reductions for tirzepatide’s Zepbound starter dose. They expressed optimism regarding the implications of these changes for pharmacies and the overall healthcare system, emphasizing the potential for improved access and wider adoption of these therapies.
In conclusion, the advancements in CGM technology, AI-supported insulin titration, and more affordable incretin-based therapies collectively represent a promising future for diabetes management. With these developments, there is an increased opportunity for enhanced patient outcomes across various clinical settings.
Both Isaacs and Bellini acknowledged their relevant disclosures, which include affiliations with organizations such as Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, and Medtronic, among others. Their insights reflect a commitment to improving diabetes care and supporting patients in their management journey.